依立雄胺联合多沙唑嗪治疗良性前列腺增生临床观察  

Clinical evaluation of combined treatment of epristeride and doxazosin for benign prostatic hyperplasia

作　　者：林云华[1] 宋丽丽[1] 王俊生[1] 姜永光[1] 

机构地区：[1]首都医科大学附属北京安贞医院泌尿科,100029

出　　处：《中国医药》2012年第2期200-201,共2页China Medicine

摘　　要：目的评价依立雄胺联合多沙唑嗪治疗中重度症状的前列腺增生的有效性。方法选择中重度症状前列腺增生患者70例，联合应用依立雄胺（5mg口服，2次／d）与多沙唑嗪控释片（4mg口服，每晚1次）治疗3个月，观察主客观症状的改善及指标变化。结果70例患者观察过程中，4例因出现不能耐受的体位性低血压、1例因反复尿潴留改用手术治疗而停药。65例患者治疗3个月后，国际前列腺症状评分[（16．12±5．82）分比（23．21±7．61）分]、生活质量评分[（2．65±0．70）分比（4．28±0．60）分]、血清前列腺特异抗原[（2．43±1．98）μg／L比（2．85±223）μg／L]和残余尿量[（33±35）ml比（49±40）m1]均比治疗前明显降低（P〈0．01）；最大尿流率比治疗前明显增多[（11．63±3．70）比（8．92±3．87）ml／s，P〈0．01]；前列腺体积减小[（38±16）m1比（40±13）m1]，但与治疗前相比无统计学差异（P〉0．05）。结论依立雄胺联合多沙唑嗪治疗中重度症状的前列腺增生有效，可作为联合用药的一种选择。Objective To evaluate the effect of combination treatment of epristeride and doxazosin for be nign prostatic hyperplasia with moderate to severe symptoms. Methods Seventy outpatients with benign prostatic hyperplasia with moderate to severe symptoms were selected randomly during 2010-10 to 2011-03 and received epris teride 5 mg po bid and doxazosin 4mg po qn for 3 months ; the effect and complication were observed. Results The international prostate symptom score （IPSS） was improved from （16. 12± 5.82） to （23.21 ± 7. 61 ） ; quality of life was improved from （2. 65 ±0.70） to （4.28 ±0. 60） ; serum PSA level decreased from （2.43 ± 1.98） to （2. 85 ± 2. 23 ）μg/L; the residual urine decreased from （ 33± 35 ） to （ 49 ± 40 ） ml and maximum flow rate increased from （ 11.63 ±3.70 ） to （ 8.92 ± 3.87 ） ml/s （ all P 〈 0. 01 ）. Although the prostate volume decreased from （ 38± 16 ） to （40 ± 13 ） ml, the result had no significant difference. Conclusion Combination treatment of epristeride and doxazosin is an effective option for treating benign prostatic hyperplasia with moderate to severe symptoms.

关 键 词：良性前列腺增生 依立雄胺 多沙唑嗪 

分 类 号：R697[医药卫生—泌尿科学]